Frequency of human leukocyte antigens class II-DR alleles (HLA-DRB1) in Argentinian patients with early arthritis.


Journal

Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 25 06 2018
accepted: 26 09 2018
revised: 07 09 2018
pubmed: 12 10 2018
medline: 14 6 2019
entrez: 12 10 2018
Statut: ppublish

Résumé

Patients with rheumatoid arthritis (RA) or undifferentiated arthritis (UA) in the CONAART database (Argentine Consortium for Early Arthritis) were assessed for genetic risk factors for RA, specifically for HLA-DRB1 alleles and the PTPN22 rs2476601 polymorphism associated with progression to RA. This is a case-control study. Blood samples were obtained to determine HLA-DRB1 genotypes by PCR-SSO Luminex and PTPN22 (rs2476601) polymorphism by allelic discrimination. A control group of individuals from the general Argentinian population were obtained from the national register of cadaveric organ donors. A total of 1859 individuals were included in this analysis: 399 patients from the CONAART database (347 patients with RA at study end and 52 patients with UA at study end, mean follow-up time 25 ± 18 months) and 1460 individuals from the general Argentinian population. Compared with the controls, the HLA-DRB1*04 and DRB1*09 alleles were more commonly detected in patients with RA diagnosis (OR (95% CI) 2.23 (1.74-2.85) and 1.89 (1.26-2.81)) respectively. Both patients with UA and the general population showed higher frequency of DRB1*07, DRB1*11 and DRB1*15 alleles than patients with RA. PTPN22 rs2476601 polymorphism frequency was higher in RA and UA vs the general population; however, this was significantly different only for RA vs control group (OR [95% CI] = 1.81 [1.10-3.02], P = 0.018. HLA-DRB1 typing and PTPN22 allelic discrimination could distinguish between patients with UA, patients with early RA, and the general population in Argentina. This is the first study of HLA-DRB1 alleles and PTPN22 polymorphism associations with progression to early RA in an Argentinian population.

Identifiants

pubmed: 30306282
doi: 10.1007/s10067-018-4319-4
pii: 10.1007/s10067-018-4319-4
doi:

Substances chimiques

HLA-DRB1 Chains 0
HLA-DRB1*04 antigen 0
HLA-DRB1*07 antigen 0
HLA-DRB1*11 antigen 0
HLA-DRB1*15 antigen 0
PTPN22 protein, human EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 22 EC 3.1.3.48

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

675-681

Références

Arthritis Rheum. 1999 Jul;42(7):1329-38
pubmed: 10403259
Ann Rheum Dis. 2001 Aug;60(8):791-5
pubmed: 11454644
J Rheumatol. 2001 Jul;28(7):1486-91
pubmed: 11469451
Genes Immun. 2002 Feb;3(1):56-8
pubmed: 11857065
Br J Rheumatol. 1992 Aug;31(8):519-25
pubmed: 1386548
N Engl J Med. 1978 Apr 20;298(16):869-71
pubmed: 147420
Hum Immunol. 2004 Mar;65(3):262-9
pubmed: 15041166
Am J Hum Genet. 2004 Aug;75(2):330-7
pubmed: 15208781
Arthritis Rheum. 2004 Oct;50(10):3085-92
pubmed: 15476204
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S12-7
pubmed: 15552509
Genes Immun. 2005 Oct;6(7):628-31
pubmed: 16163373
J Clin Rheumatol. 2004 Jun;10(3):110-5
pubmed: 17043481
Am J Hum Genet. 2007 May;80(5):867-75
pubmed: 17436241
Autoimmun Rev. 2007 Jun;6(6):402-8
pubmed: 17537386
Am Fam Physician. 2008 May 15;77(10):1451-3
pubmed: 18533381
Rheumatology (Oxford). 2011 Jan;50(1):110-6
pubmed: 20663815
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Nat Rev Rheumatol. 2011 Jun 14;7(7):381-90
pubmed: 21670767
Rev Bras Reumatol. 2011 Sep-Oct;51(5):474-83
pubmed: 21952999
Autoimmun Rev. 2012 Jun;11(8):589-92
pubmed: 22037115
Clin Exp Rheumatol. 2012 Jul-Aug;30(4):520-4
pubmed: 22704547
Immunol Lett. 2012 Sep;147(1-2):41-6
pubmed: 22743847
Clin Rheumatol. 2016 Jun;35(6):1457-62
pubmed: 26951256
J Rheumatol. 2017 Feb;44(2):154-161
pubmed: 28089976
Immunogenetics. 2017 Aug;69(8-9):597-603
pubmed: 28695293
Ann Rheum Dis. 1997 Mar;56(3):191-3
pubmed: 9135224
Hum Immunol. 1998 May;59(5):287-94
pubmed: 9619767

Auteurs

Gustavo Citera (G)

Instituto de Rehabilitación Psicofísica, Echeverría 955, 1429, Buenos Aires, Argentina. gustavocitera@gmail.com.

Fernando Dal Pra (FD)

Instituto de Rehabilitación Psicofísica, Echeverría 955, 1429, Buenos Aires, Argentina.

Christian A Waimann (CA)

Hospital Dr. Hector Cura de Olavarria, Buenos Aires, Argentina.

Hernan Maldonado Ficco (HM)

Instituto de Rehabilitación Psicofísica, Echeverría 955, 1429, Buenos Aires, Argentina.

Teresita Alvarellos (T)

Hospital Privado e Instituto Universitario de Ciencias Biomédicas, Cordoba, Argentina.

Luciana A Mas (LA)

Hospital Privado e Instituto Universitario de Ciencias Biomédicas, Cordoba, Argentina.

Osvaldo L Cerda (OL)

Instituto de Rehabilitación Psicofísica, Echeverría 955, 1429, Buenos Aires, Argentina.

Sergio Paira (S)

Hospital Dr. José María Cullen, Santa Fe, Argentina.

Antonio Catalán Pellet (AC)

Hospital Rivadavia, Buenos Aires, Argentina.

Anastasia Secco (A)

Hospital Rivadavia, Buenos Aires, Argentina.

Lucila Marino (L)

Hospital Rivadavia, Buenos Aires, Argentina.

María Martire (M)

Hospital Rivadavia, Buenos Aires, Argentina.

Josefina Marcos (J)

Hospital San Martín, La Plata, Buenos Aires, Argentina.

Mercedes A García (MA)

Hospital San Martín, La Plata, Buenos Aires, Argentina.

Adrián Salas (A)

Hospital San Martín, La Plata, Buenos Aires, Argentina.

Alberto Berman (A)

Centro Médico Privado de Reumatología, Tucuman, Argentina.

Horacio Berman (H)

Centro Médico Privado de Reumatología, Tucuman, Argentina.

Oscar L Rillo (OL)

Hospital Pirovano, Buenos Aires, Argentina.

Liliana Vargas (L)

Hospital Pirovano, Buenos Aires, Argentina.

Edson Velozo (E)

Sanatorio y Universidad Adventista, Libertador San Martin, Puiggari, Argentina.

Ricardo Vicente Juarez (RV)

Hospital Senor del Milagro Salta, Salta, Argentina.

María Elena Crespo Espindola (MEC)

Hospital Senor del Milagro Salta, Salta, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH